Comparison 12: SNRIs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 261 participantsLow
Comparison 12: SNRIs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 261 participantsLow
Comparison 13: SSRIs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted14 studies · 1990 participantsLow
Comparison 13: SSRIs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 1173 participantsLow
Comparison 13: SSRIs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 1173 participantsLow
Comparison 2: anticonvulsants/GABAs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 69 participantsLow
Comparison 15: NK1 receptor antagonist GR205171 vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 24 participantsVery low
Comparison 16: LY686017 vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 99 participantsVery low
Comparison 2: anticonvulsants/GABAs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 69 participantsLow
Comparison 2: anticonvulsants/GABAs vs placeboReduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD1 finding from 1 reviewPharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes onlyno estimate extracted1 study · 69 participantsLow
Paroxetine vs placeboSymptom severity reductionLSAS · people with anxiety and comorbid alcohol use disorders1 finding from 1 reviewPharmacotherapy for anxiety and comorbid alcohol use disorders 2015 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 44 participantsVery low
Paroxetine vs placeboDepression symptom reduction · people with anxiety and comorbid alcohol use disorders1 finding from 1 reviewPharmacotherapy for anxiety and comorbid alcohol use disorders 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 15 participantsVery low
Glutamate modulators vs placeboReduction of TTM symptom severityMassachusetts General Hospital Hair‐Pulling Scale (MGH‐HPS) · children and adolescents with trichotillomania1 finding from 1 reviewPharmacotherapy for trichotillomania 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 39 participantsLow